Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Hematologic and Solid Tumor Cancers

Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Hematologic and Solid Tumor Cancers

European Hematology Association (EHA) 2024

Aditi Shastri, Tatyana Feldman, Stefan K. Barta, Adam J. Olszewski, Auris O. Huen, Stephen D. Smith, Eric J. Feldman, Zachary D. Epstein-Peterson, Don A. Stevens, Pierluigi Porcu, Alexander N. Starodub, John C. Reneau, Jonathan E. Brammer, Ahmad Mattour, Lauren Pinter-Brown, Cristina P. Rodriguez, Ashwin Gollerkeri, Rachelle Perea, Joyoti Dey, Sean Donohue, Sagar Agarwal, Alyssa Fasciano, Jared Gollob, Enrica Marchi